Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEROME R OBED

Allopathic & Osteopathic Physicians Dermatology

NPI
1720055585
CMS profile
169015
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$28,076.45

151 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEROME R OBED

NPI 1720055585 · CMS profile ID 169015

Allopathic & Osteopathic Physicians / Dermatology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1720055585?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEROME R OBED, NPI 1720055585, CMS profile ID 169015. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1720055585?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JEROME R OBED, NPI 1720055585, CMS profile ID 169015. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1720055585?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JEROME R OBED, NPI 1720055585, CMS profile ID 169015, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1720055585?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

151 matching records · $28,076.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 151 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 151.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Almirall LLC $15.1004/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038206289 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.9804/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996887549 CMS
Almirall LLC $26.3704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038206345 CMS
Galderma Laboratories, L.P. $40.7804/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059717319 CMS
Amgen Inc. $26.8804/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020600355 CMS
ConvaTec Inc. $5,625.0004/12/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057550199 CMS
Kerecis Limited $168.3004/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056292389 CMS
GENZYME CORPORATION $36.6404/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050025757 CMS
Lilly USA, LLC $31.8804/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031582153 CMS
UCB, Inc. $22.0804/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021568031 CMS
ABBVIE INC. $6.9903/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998032023 CMS
PFIZER INC. $20.6803/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049142131 CMS
PFIZER INC. $121.3103/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050357849 CMS
UCB, Inc. $1.1203/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021568019 CMS
UCB, Inc. $18.1103/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021568025 CMS
Organogenesis Inc. $24.0703/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048164375 CMS
E.R. Squibb & Sons, L.L.C. $3.3403/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212127 CMS
E.R. Squibb & Sons, L.L.C. $3.3303/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212133 CMS
ABBVIE INC. $20.4403/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998032019 CMS
GENZYME CORPORATION $23.4003/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050025741 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.9303/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996887551 CMS
ABBVIE INC. $8.5203/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998032015 CMS
Dermavant Sciences, Inc. $2.9503/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991233437 CMS
PFIZER INC. $2.3703/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049124841 CMS
Janssen Biotech, Inc. $19.7003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988672375 CMS
PFIZER INC. $1.4803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049492363 CMS
GENZYME CORPORATION $34.3802/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050025725 CMS
ConvaTec Inc. $118.7002/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057550195 CMS
PFIZER INC. $4.3102/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050510365 CMS
ABBVIE INC. $124.9902/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998032011 CMS
ConvaTec Inc. $109.1902/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057550191 CMS
Janssen Biotech, Inc. $20.0002/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988672383 CMS
Novartis Pharmaceuticals Corporation $30.3402/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992921171 CMS
PFIZER INC. $15.2702/10/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049566855 CMS
PFIZER INC. $18.8902/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050622543 CMS
Regeneron Healthcare Solutions, Inc. $28.4402/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999337315 CMS
ABBVIE INC. $26.3002/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998032007 CMS
Novartis Pharmaceuticals Corporation $27.0502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992921169 CMS
Janssen Biotech, Inc. $21.0801/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988672381 CMS
Janssen Biotech, Inc. $1.9401/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988672385 CMS
Regeneron Healthcare Solutions, Inc. $28.9301/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999337309 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $33.1901/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996887555 CMS
E.R. Squibb & Sons, L.L.C. $118.7601/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212251 CMS
E.R. Squibb & Sons, L.L.C. $3.0001/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212091 CMS
Janssen Biotech, Inc. $2.1901/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988672391 CMS
ABBVIE INC. $9.5701/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998032003 CMS
UCB, Inc. $22.7101/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021568043 CMS
E.R. Squibb & Sons, L.L.C. $25.4001/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212087 CMS
Amgen Inc. $22.4701/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020600353 CMS
Galderma Laboratories, L.P. $17.0701/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059717317 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,702.10 145
PY2020 $4,949.98 95
PY2021 $3,174.25 123
PY2022 $16,297.78 153
PY2023 $28,076.45 151
PY2024 $39,897.60 199
PY2025 $53,008.37 200

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $656,671.49 19
PY2024 Recipient $6,826.58 3
PY2024 Principal investigator $186,714.24 8
PY2021 Principal investigator $12,798.21 35
PY2020 Principal investigator $47,908.54 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI PASTEUR INC. $18,857.25 12/22/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108828
Principal investigator 1 SANOFI PASTEUR INC. $1,775.00 12/10/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108818
Principal investigator 1 SANOFI PASTEUR INC. $2,050.00 12/10/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108824
Principal investigator 1 SANOFI PASTEUR INC. $400.00 12/02/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108813
Principal investigator 1 SANOFI PASTEUR INC. $32,600.00 11/19/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108778
Principal investigator 1 SANOFI PASTEUR INC. $1,600.00 11/18/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108806
Principal investigator 1 SANOFI PASTEUR INC. $13,624.20 11/14/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108799
Principal investigator 1 SANOFI PASTEUR INC. $5,525.00 11/13/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108792
Principal investigator 1 SANOFI PASTEUR INC. $36,357.30 10/31/2025 Non-covered Recipient Entity
Encore Medical Research Llc
A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunogenicity of an Acne mRNA Vaccine Candidate in Adults With Moderate to Severe Acne 18 to 45 Years of Age No dispute reported 06/30/2026 1226108787
Principal investigator 1 Eli Lilly and Company $97,188.00 08/28/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187880907
Principal investigator 1 Eli Lilly and Company $11,307.31 07/17/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187879013
Principal investigator 1 Eli Lilly and Company $13,271.00 07/08/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, 52 WEEK STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN THE TREATMENT OF ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880225
Principal investigator 1 Eli Lilly and Company $33,236.00 06/02/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880227
Principal investigator 1 Eli Lilly and Company $155,784.00 05/27/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187879927
Principal investigator 1 Eli Lilly and Company $10,662.15 04/23/2025 Non-covered Recipient Entity
CAPITAL CLINICAL RESEARCH CENTER PLLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187878347
Principal investigator 1 Eli Lilly and Company $6,803.17 01/27/2025 Non-covered Recipient Entity
CAPITAL CLINICAL RESEARCH CENTER PLLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187878257
Principal investigator 1 Eli Lilly and Company $403.11 01/27/2025 Non-covered Recipient Entity
CAPITAL CLINICAL RESEARCH CENTER PLLC
A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880631
Principal investigator 1 Eli Lilly and Company $19,674.00 01/21/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
A STUDY OF LY3454738 IN THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187883062
Principal investigator 1 Eli Lilly and Company $195,554.00 01/07/2025 Non-covered Recipient Entity
ENCORE MEDICAL RESEARCH, LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187879017